| Treatment for Churg-Strauss syndrome: induction of remission and efficacy of intravenous immunoglobulin therapy. | |
| | |
MedLine Citation:
|
PMID: 17460439 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Churg-Strauss syndrome (CSS) is characterized by the presence of asthma, eosinophilia, and small-vessel vasculitis with granuloma. It is a distinct entity, as determined from all classifications of systemic vasculitis. The poor prognostic factors in CSS are renal insufficiency, cardiomyopathy, severe gastrointestinal (GI) tract, and central nervous systems (CNS) involvement. The initial management of CSS should include a high dose of a corticosteroid: prednisone at 1 mg/kg/day or its equivalent for methylprednisolone with tapering over 6 months. In patients with severe or rapidly progressing CSS, the administration of methylprednisolone pulse at 1 g/body/day for 3 days is recommended. When corticosteroid therapy does not induce remission, or when patients have poor prognostic factors, immunosuppressive cytotoxic therapy is indicated. However, some patients with severe CSS often show resistance to conventional treatment. We think that IVIG therapy is a hopeful candidate for second-line treatment for CSS patients, particularly in the case of neuropathy and/or cardiomyopathy, which are resistant to conventional therapy. However, there is not much evidence supporting the effectiveness of IVIG in CSS, and the mechanisms underlying the action of IVIG remain unclear. Now we are performing clinical trials of IVIG therapy for CSS patients who are resistant to conventional treatment, through a nationwide double-blinded placebo-controlled study in Japan. |
| | |
Authors:
|
Masami Taniguchi; Naomi Tsurikisawa; Noritaka Higashi; Hiroshi Saito; Haruhisa Mita; Akio Mori; Hiroki Sakakibara; Kazuo Akiyama |
Related Documents
:
|
4003919 - The efficacy of orally administered theophylline, inhaled salbutamol, and a combination... 19240379 - Adherence with long-term asthma management in patients who experienced hospitalized ast... 7920609 - A controlled trial of pulse cyclophosphamide versus pulse methylprednisolone in severe ... 8200169 - Intravenous immunoglobulin in the treatment of salmonella typhimurium infections in pre... 15513449 - Treatment of acute demyelinating optic neuritis. 15477549 - Multifocal motor neuropathy: decrease in conduction blocks and reinnervation with long-... 10528769 - Long-term results of lateral internal sphincterotomy for chronic anal fissure with part... 4003919 - The efficacy of orally administered theophylline, inhaled salbutamol, and a combination... 7795999 - Island advancement flaps in the management of anal fissures. |
Publication Detail:
|
Type: Journal Article; Review Date: 2007-05-01 |
Journal Detail:
|
Title: Allergology international : official journal of the Japanese Society of Allergology Volume: 56 ISSN: 1323-8930 ISO Abbreviation: Allergol Int Publication Date: 2007 Jun |
Date Detail:
|
Created Date: 2007-05-29 Completed Date: 2007-08-09 Revised Date: 2008-03-06 |
Medline Journal Info:
|
Nlm Unique ID: 9616296 Medline TA: Allergol Int Country: Japan |
Other Details:
|
Languages: eng Pagination: 97-103 Citation Subset: IM |
Affiliation:
|
National Hospital Organization, Sagamihara National Hospital, Kanagawa, Japan. m-taniguchi@sagamihara-hosp.gr.jp |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adrenal Cortex Hormones
/
therapeutic use Antibodies, Monoclonal / therapeutic use Biological Markers / urine Churg-Strauss Syndrome / drug therapy*, immunology, urine Cyclophosphamide / therapeutic use Humans Immunoglobulins, Intravenous / therapeutic use* Immunologic Factors / therapeutic use* Immunosuppressive Agents / therapeutic use Interferon-alpha / therapeutic use Leukotriene E4 / urine Methylprednisolone / therapeutic use Plasma Exchange Prednisolone / therapeutic use Remission Induction Salvage Therapy* Treatment Failure Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Adrenal Cortex Hormones; 0/Antibodies, Monoclonal; 0/Biological Markers; 0/Immunoglobulins, Intravenous; 0/Immunologic Factors; 0/Immunosuppressive Agents; 0/Interferon-alpha; 50-18-0/Cyclophosphamide; 50-24-8/Prednisolone; 75715-89-8/Leukotriene E4; 83-43-2/Methylprednisolone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: ANCA-associated vasculitis: diagnostic and therapeutic strategy.
Next Document: Therapeutic strategies for systemic necrotizing vasculitides.